Triple-Negative Breast Cancer

Might a Chemical from Celery and Broccoli One Day Yield a New Drug to Prevent Breast Cancer Metastasis?

Might a Chemical from Celery and Broccoli One Day Yield a New Drug to Prevent Breast Cancer Metastasis?

By

Investigators report on their findings from preclinical studies of luteolin injections to prevent lung metastases of triple-negative breast cancer.

New Use of an Old Drug Could Address Cancer Metastasis

New Use of an Old Drug Could Address Cancer Metastasis

By

CDK 4/6 inhibitors, currently approved for the treatment of estrogen-positive breast cancer, were found to inhibit metastasis in triple-negative breast

High Immune Gene Expression Linked to Better Prognosis in TNBC

High Immune Gene Expression Linked to Better Prognosis in TNBC

By

Researchers assessed the relationship between immune gene expression and genomic complexity in TNBC in a study presented at SABCS 2016.

Study Identifies Patients Who May Derive More Benefit From Veliparib

Study Identifies Patients Who May Derive More Benefit From Veliparib

By

At SABCS 2016, researchers presented study findings demonstrating whether neoadjuvant treatment, PARPi-7, BRCAness, and MP1/2 predict response to veliparib plus carboplatin therapy in patients with high-risk breast cancer.

Prolactin Expression May Indicate Better Prognosis for Patients With TNBC

Prolactin Expression May Indicate Better Prognosis for Patients With TNBC

By

Expression of this hormone receptor may indicate a less aggressive subtype of triple-negative breast cancer and better prognosis for patients with the disease.

Experimental Drug Improves Immunotherapy Activity in Triple-Negative Breast Cancer

Experimental Drug Improves Immunotherapy Activity in Triple-Negative Breast Cancer

By

An experimental drug, AMPI-109, shows promise as an immunotherapy that sensitizes triple-negative breast cancer cells, enhancing the effectiveness of the drug.

Triplet Regimen Followed by Maintenance Active in Triple-negative Breast Cancer

Triplet Regimen Followed by Maintenance Active in Triple-negative Breast Cancer

By

A first-line triplet chemoimmunotherapy regimen comprised of paclitaxel, capecitabine, and bevacizumab followed by capecitabine and bevacizumab alone as maintenance therapy is highly active with a manageable safety profile in patients with triple-negative breast cancer.

Triple-Drug Therapy Produces Response in Triple-Negative Breast Cancer, Mouse Study Shows

Triple-Drug Therapy Produces Response in Triple-Negative Breast Cancer, Mouse Study Shows

By

A cocktail of 3 drugs shrank triple-negative breast cancer (TNBC) by killing off cancer cells and halting new tumor growth, a new study conducted in mice and lab-grown human cells has shown.

Vitamin D and Androgen Receptor-Targeted Therapy Are Effective in Triple-Negative Breast Cancer

By

Vitamin D and androgen receptor-targeted therapy successfully reduced growth and induced death of cancerous cells in a cell culture model of triple-negative breast cancer.

Drug Candidate Successful in Targeting Cancer-Causing RNA

By

A new drug candidate reduced the growth of tumors in a mouse model of triple negative breast cancer (TNBC) by targeting the RNA, or expression, of a gene only expressed in the diseased cells.

Gene Alterations May Explain Treatment Resistance of Triple-negative Breast Cancer

Gene Alterations May Explain Treatment Resistance of Triple-negative Breast Cancer

By

Amplification of the JAK2 gene frequently occurs in triple-negative breast cancer (TNBC), suggesting that specific inhibitors of JAK2 should be investigated in TNBC.

A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer

A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer

[Breast Cancer: Basic and Clinical Research] The review examines the standard systemic and future treatment options in metastatic triple-negative breast cancer.

Beta Blockers Halt Progression of Aggressive Breast Cancer Cell Line

By

Adrenaline acted on breast cancer cells via the cell surface beta2-adrenoceptor to promote disease growth and invasion, suggesting that beta-blockers might be helpful as adjuvant therapy for patients with aggressive breast cancer.

Adding Carboplatin to Neoadjuvant Therapy for Triple-negative Early Breast Cancer Improves Disease-free Survival

Adding Carboplatin to Neoadjuvant Therapy for Triple-negative Early Breast Cancer Improves Disease-free Survival

By

Carboplatin added to anthracycline/taxane-based neoadjuvant chemotherapy significantly improved pathological complete response rates in patients with triple-negative breast cancer in two large phase IIb studies: GeparSixto and CALGB 40603. Researchers reported on disease-free survival for GeparSixto after median 35 months of observation at the 2015 San Antonio Breast Cancer Symposium.

New Therapy for Triple-negative Breast Cancer Shows Promise in Laboratory Studies

By

Recent laboratory findings provide novel insight into potential new therapeutic approaches for triple-negative breast cancer, a particularly difficult-to-treat and aggressive form of the disease.

Understanding the Triple Negative Breast Cancer Patient: Tips and Tools for Health Care Professionals

Understanding the Triple Negative Breast Cancer Patient: Tips and Tools for Health Care Professionals

By

Although treatment options are different and recurrence rates higher for triple negative breast cancer, patients with this subtype of the disease can be hopeful for good treatment outcomes.

Dietary intervention primes triple-negative breast cancer cells for targeted therapy

Dietary intervention primes triple-negative breast cancer cells for targeted therapy

By

A diet that starves triple-negative breast cancer cells of an essential nutrient primes the cancer cells to be more easily killed by targeted treatment.

Enzalutamide May Represent Novel Therapeutic Option for Triple-Negative Breast Cancer

Enzalutamide May Represent Novel Therapeutic Option for Triple-Negative Breast Cancer

By

Enzalutamide may be a viable alternative therapy over cytotoxic chemotherapy for individuals with triple-negative breast cancer, according to a study presented at the 2015 American Society of Clinical Oncology annual meeting.

Triple-negative breast cancer is distinctly different in African American women

Triple-negative breast cancer is distinctly different in African American women

By

A new study reveals specific genetic alterations that appear to impact the prognosis and survival rates of African American women.

Immune therapy tested for triple-negative breast cancer

By

Preliminary study results indicate that an experimental immune system drug is generally safe and well tolerated in women with metastatic, triple-negative breast cancer.

The switch that might tame the most aggressive of breast cancers

By

Researchers have learned more about breast cancer, including identification of a gene that drives the aggressive disease.

Epigenetic signatures differentiate triple negative breast cancers

By

Specific methylation patterns revealed in the primary biopsy breast cancer cells of breast cancer DNA methylome can indicate a better or worse prognosis.

Effectiveness of nanoparticle drugs was hindered by tumor microenvironment in triple-negative breast cancer

By

Nanoparticle drugs were considered to be a potential silver bullet against cancer, but they have not produced the anticipated improvement in overall survival rates.

Pembrolizumab safe, and even effective in some patients, for triple-negative breast cancer

By

Pembrolizumab was well tolerated and yielded durable responses in patients with metastatic triple-negative breast cancer, according to recent trial data.

Inherited mutations typical in triple-negative breast cancer

Inherited mutations typical in triple-negative breast cancer

Deleterious mutations were identified in 14.6 percent of patients in a cohort unselected for family history.

Adding drugs to standard chemotherapy improves response in triple-negative breast cancer

Adding drugs to standard chemotherapy improves response in triple-negative breast cancer

By

Adding carboplatin and/or bevacizumab to the standard treatment regimen significantly improved pathologic complete response rates in patients with triple-negative breast cancer, according to a new phase 2 study.

Some aggressive cancers may respond to anti-inflammatory drugs

By

New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs currently used to treat rheumatoid arthritis.

Anti-androgen therapy may benefit wider spectrum of patients with triple-negative breast cancer

By

Up to a third of triple-negative breast cancer tumors express the androgen receptor. Trails are underway with drugs to inhibit the androgen receptor in much the same way that tamoxifen inhibits the estrogen receptor in ER-positive breast cancers.

Leukemia gene leads to potential target for triple-negative breast cancer treatment

Leukemia gene leads to potential target for triple-negative breast cancer treatment

Scientists have discovered that a gene previously linked to leukaemia could provide an urgently needed target for the development of drugs to treat patients with 'triple negative' breast cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs